These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25630559)

  • 1. Infection risk associated with anti-TNF-α agents: a review.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
    Expert Opin Drug Saf; 2015 Apr; 14(4):571-82. PubMed ID: 25630559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update upon the infection risk in patients receiving TNF alpha inhibitors.
    Murdaca G; Negrini S; Pellecchio M; Greco M; Schiavi C; Giusti F; Puppo F
    Expert Opin Drug Saf; 2019 Mar; 18(3):219-229. PubMed ID: 30704314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infections and Biological Therapy in Patients with Rheumatic Diseases.
    Atzeni F; Batticciotto A; Masala IF; Talotta R; Benucci M; Sarzi-Puttini P
    Isr Med Assoc J; 2016; 18(3-4):164-7. PubMed ID: 27228636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
    Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
    Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of etanercept in chronic immune-mediated disease.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
    Expert Opin Drug Saf; 2014 May; 13(5):649-61. PubMed ID: 24654562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis.
    Campanati A; Paolinelli M; Diotallevi F; Martina E; Molinelli E; Offidani A
    Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):913-925. PubMed ID: 31623470
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis.
    Murdaca G; Spanò F; Puppo F
    Expert Opin Drug Saf; 2013 Nov; 12(6):801-4. PubMed ID: 23889669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis.
    Tong Q; Cai Q; de Mooij T; Xu X; Dai S; Qu W; Zhao D
    PLoS One; 2015; 10(3):e0119897. PubMed ID: 25764452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
    Winthrop KL
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.
    Salmon-Ceron D; Tubach F; Lortholary O; Chosidow O; Bretagne S; Nicolas N; Cuillerier E; Fautrel B; Michelet C; Morel J; Puéchal X; Wendling D; Lemann M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2011 Apr; 70(4):616-23. PubMed ID: 21177290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature.
    Domm S; Cinatl J; Mrowietz U
    Br J Dermatol; 2008 Dec; 159(6):1217-28. PubMed ID: 18945310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
    Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
    Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis].
    Xie X; Chen J; Peng Y; Gao J; Tian J; Ling G; Du J; Mao N; Wu P; Li F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 38(7):722-36. PubMed ID: 23908082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.